Predicate |
Object |
assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_3fc6c2e9e63b6561f2f46b1de31f6379 |
classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P29-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-18 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-365 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-42 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-415 |
classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-46 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-48 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-365 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-20 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-22 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P29-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-26 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-42 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-415 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-19 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-20 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-08 |
filingDate |
2002-11-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
grantDate |
2008-05-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_66311d7319851c8116c99adfd84a1908 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5d4a1082283ad81efc04f2b4aa7aef61 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f2b4b02e898a8a715dfd1dad84791f28 |
publicationDate |
2008-05-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber |
ES-2297032-T3 |
titleOfInvention |
ORAL DOSAGE FORM OF PARECOXIB. |
abstract |
The use of parecoxib as its free acid or its pharmaceutically acceptable water-soluble salt for the manufacture of a composition for the treatment or prevention of a COX-2 mediated disorder in a subject, in which the composition is substantially free of water, is administered orally, and has means to inhibit the degradation of parecoxib to valdecoxib selected from: - a sealed container or container substantially impermeable to water; - a coating substantially impermeable to water; - a formulation of the composition that has substantially no amount of any excipient that tends to stimulate such conversion when it is in intimate contact with parecoxib or its water-soluble salt; - a formulation of the composition having a barrier layer between parecoxib or its water-soluble salt and an excipient that tends to stimulate said conversion; and wherein the treatment consists of dissolving at least one dosage unit of the composition in a pharmaceutically acceptable aqueous vehicle to form a solution that is administered orally to the subject before a substantial precipitation of insoluble matter in the solution occurs. |
priorityDate |
2001-11-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type |
http://data.epo.org/linked-data/def/patent/Publication |